(Q54485562)

English

Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/22957712

Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors. (English)

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/22957712

0 references

author name string

Isamu Okamoto

1

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/22957712

Tokuzo Arao

2

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/22957712

Masaki Miyazaki

3

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/22957712

Taroh Satoh

4

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/22957712

Kunio Okamoto

5

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/22957712

Takuya Tsunoda

6

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/22957712

Kazuto Nishio

7

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/22957712

Kazuhiko Nakagawa

8

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/22957712

publication date

14 October 2012

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/22957712

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/22957712

103

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/22957712

12

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/22957712

2135-2138

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/22957712

Clinical translation of angiogenesis inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12014

21 January 2018

Molecular mechanisms and clinical applications of angiogenesis

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12014

21 January 2018

Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12014

21 January 2018

Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12014

21 January 2018

A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth

2 references

https://api.crossref.org/works/10.1111%2FCAS.12014

21 January 2018

https://pubmed.ncbi.nlm.nih.gov/22957712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12014

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12014

21 January 2018

Identification of expressed genes characterizing long-term survival in malignant glioma patients

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12014

21 January 2018

Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12014

21 January 2018

Vaccines targeting the neovasculature of tumors

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12014

21 January 2018

HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12014

21 January 2018

Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events.

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12014

21 January 2018

The multifaceted circulating endothelial cell in cancer: towards marker and target identification.

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12014

21 January 2018

Clinical biomarkers of angiogenesis inhibition

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12014

21 January 2018

Microarray analysis for a comprehensive immunological-status evaluation during cancer vaccine immune monitoring

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12014

21 January 2018

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12014

21 January 2018

Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12014

21 January 2018

Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12014

21 January 2018

Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/22957712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/22957712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1

1 reference

https://pubmed.ncbi.nlm.nih.gov/22957712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/CAS.12014

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/22957712

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/22957712

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54485562&oldid=1547507203"